Epigenuity is a physician-scientist-founded research company developing decision-support software and diagnostic platforms across maternal health, oncology, and acute care.
"The hardest problems in medicine aren't in the lab — they're in the workflow gap between evidence and bedside. We build the bridge."
Decision-support and consumer-health apps developed independently by Epigenuity LLC. Each provides educational or clinical decision support and is not a regulated medical device or a substitute for professional judgment.
Postpartum-hemorrhage risk assessment and maternal-safety compliance for labor & delivery teams. CMQCC, AWHONN, and ACOG scoring, a Maternal Safety Suite (bundle checklist, QBL, MTP timer, handoff), and automated Joint Commission / AIM / CMQCC compliance reports. Runs in-browser with no PHI transmitted; SMART-on-FHIR launch supported.
Web app · pphrisk.com · clinical decision support, not a medical device
A pregnancy, postpartum, and nursing companion that gives clear, sourced answers — scan a barcode or label, ask a question, and see guidance personalized to your gestational week, with every answer linked to sources such as ACOG, CDC, FDA, and MotherToBaby. Private by design. Educational information, not medical advice.
iOS & Android · epipreg.com · educational use only
A patient-facing guidance app that answers everyday medical questions with plain-language, evidence-based explanations grounded in peer-reviewed literature and national guidelines — with citations you can read yourself and follow-up questions that build on the conversation. Educational information, not medical advice.
iOS app · in App Store review · educational use only
Additional diagnostic and device programs are in development and will be listed once the company completes the appropriate intellectual-property and licensing arrangements with the relevant institutions.
Three free, browser-based engines that turn a gene name into a synthesis-ready RNA-therapeutic design — no coding, no sequence files. Each is open-source (MIT), archived with a citable DOI, and developed by Ravi Goyal, MD, PhD, Epigenuity LLC. In-silico design only; confirm experimentally. Not medical devices.
Maps the critical protein-binding element of a disease-driving lncRNA or toxic repeat RNA and designs a steric-block / decoy disruptor that neutralizes the RNA–protein scaffold without degrading the transcript.
Open-source (MIT) · DOI 10.5281/zenodo.20615550
Designs a protein-free RNA AND-gate device that degrades a target transcript only where a disease-defining trigger RNA is also present — single-cell coincidence detection. Returns the device, predicted OFF/ON folding, and single-nucleotide discrimination.
Open-source (MIT) · DOI 10.5281/zenodo.20673364
Designs a programmable RNA “death tag” that redirects the cell’s own RNA-surveillance machinery (nuclear exosome / NMD) to destroy a chosen transcript — including de-protection of structurally shielded 3′ ends. Returns the antisense binding element, matched decay module, and predicted energetics + specificity.
Open-source (MIT) · DOI 10.5281/zenodo.20707857
Every Epigenuity program starts with a workflow problem observed at the bedside, not a technology looking for an application. We validate clinically before we engineer commercially.
Programs originate from real clinical gaps — bundle non-compliance, missed early AKI, late-detected breast cancer. We solve what hurts.
An evidence-first development approach spanning assay design, signal processing, and device prototyping, advanced through Epigenuity's own resources and appropriate collaborator arrangements. Phase-gated development.
Every program has a defined go-to-market path: 510(k), LDT, software, or strategic licensing. No moonshots without a path to patients.
Practicing physicians and scientists with a track record in translational research.
Physician-scientist · MD, PhD, MBA, FAHA
A physician-scientist focused on translating bedside workflow problems in maternal health, oncology, and acute care into decision-support and diagnostic tools. Founded Epigenuity to develop these products as an independent commercial venture, separate from his academic responsibilities.
We're assembling an SAB with deep expertise in maternal-fetal medicine, oncology, and digital health.
Interested in advising? →Epigenuity is actively seeking clinical and institutional research collaborators across the Southwest.
Open to new partnerships →Epigenuity is building toward federal STTR / SBIR applications and an independent intellectual-property position. Funding milestones and institutional agreements will be announced here once finalized.
For partnership, investment, or research inquiries, please get in touch.
Founder bibliography spans maternal-fetal physiology, vascular biology, IUGR, developmental epigenetics, traumatic brain injury, and translational medicine — including a 94-page review in Physiological Reviews (2018). These are the founder's independent academic publications, listed as scientific background; they are not products or work product of Epigenuity LLC.
Whether you're a clinical collaborator, investor, prospective hire, advisor, or someone from a federal agency or foundation — we want to hear from you.